^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Melanoma
    Drug:ulixertinib (BVD-523) (ERK2 inhibitor, ERK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

    Excerpt:
    ...Patients with NRAS mutated melanoma...
    Trial ID:
    NCT01781429
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

    Excerpt:
    Seventeen patients with NRAS-mutated melanoma were evaluable for response. Three patients (18%) achieved a PR, 6 had stable disease, and 8 had disease progression as best response.
    DOI:
    10.1158/2159-8290.CD-17-1119
    Trial ID:
    NCT01781429
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study.

    Excerpt:
    Ulixertinib at 600 mg twice a day has an acceptable safety profile and has produced durable responses in pts with NRAS mutant melanoma...
    DOI:
    10.1200/JCO.2017.35.15_suppl.2508
    Trial ID:
    NCT01781429